Marina Grandis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marina Grandis has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Angelo Schenone
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Largo P. Daneo 3, 16132 Genova, Italy
16 shared publications - Sara Massucco
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI), University of Genoa, Largo P. Daneo 3, 16132 Genova, Italy
10 shared publications - Stefano Tozza
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Università degli Studi di Napoli Federico II, Italia
10 shared publications - Gian Maria Fabrizi
Dipartimento di Neuroscienze, Biomedicina e Movimento, Università di Verona, Italia
9 shared publications - Luca Gentile
Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
9 shared publications - Massimo Russo
Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
9 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Open Exploration Publishing in Exploration of Neuroprotective Therapy
- Vol. 6, 1004169
Reversible very late onset myasthenia gravis following intravesical Bacillus Calmette-Guerine treatment: a case report
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder occasionally triggered by immunomodulatory therapies. While immune checkpoint inhibitors are well-recognized culprits, traditional antineoplastic treatments like intravesical Bacillus Calmette-Guerine (BCG) can also precipitate severe immune-related adverse events. We describe a rare presentation of BCG-induced MG, emphasizing the crucial diagnostic role of clinical neurophysiology in evaluating atypical focal onset. A 76-year-old male with high-grade urothelial carcinoma underwent transurethral resection followed by a standard six-week induction of intravesical BCG. Twelve days after the final instillation, he developed isolated, severe neck extensor weakness resulting in dropped head syndrome (antecollis). Following an unrevealing cervical magnetic resonance imaging scan and the failure of empirical conservative management, a comprehensive neurophysiological evaluation was strictly performed. Concentric needle electromyography of the splenius capitis muscle revealed focal myopathic alterations, including early recruitment of small motor unit potentials, positive sharp waves, and fibrillation potentials. Crucially, low-frequency repetitive nerve stimulation (RNS) of the spinal accessory nerve, recording from the trapezius, demonstrated a significant, diagnostic decremental response of the compound muscle action potential amplitude. Serological assays confirmed highly elevated anti-acetylcholine receptor antibodies. Chest computed tomography excluded thymoma, establishing the diagnosis of very late-onset generalized MG (MGFA class IIb). Initial symptomatic monotherapy with pyridostigmine lacked efficacy. However, targeted therapy combining oral prednisone (0.5 mg/kg/day) and pyridostigmine induced a dramatic, rapid resolution of the antecollis and subsequent dysphagia. Corticosteroids were progressively tapered and definitively discontinued after six months, achieving sustained clinical remission without relapses. We report the third formally documented case of very late-onset generalized MG triggered by intravesical BCG immunotherapy, hypothetically mediated by pathogenic epitope sharing between mycobacterial and self-antigens. This case distinctly highlights the pivotal diagnostic utility of RNS in differentiating acute atypical axial weakness. Furthermore, it demonstrates that BCG-induced MG exhibits a highly favourable, fully reversible prognosis following prompt, targeted corticosteroid intervention.
- 26 October 2026
- Published by Open Exploration Publishing in Exploration of Neuroprotective Therapy
- Vol. 6, 1004169
Open AccessReversible very late onset myasthenia gravis following intravesical Bacillus Calmette-Guerine treatment: a case report
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder occasionally triggered by immunomodulatory therapies. While immune checkpoint inhibitors are well-recognized culprits, traditional antineoplastic treatments like intravesical Bacillus Calmette-Guerine (BCG) can also precipitate severe immune-related adverse events. We describe a rare presentation of BCG-induced MG, emphasizing the crucial diagnostic role of clinical neurophysiology in evaluating atypical focal onset. A 76-year-old male with high-grade urothelial carcinoma underwent transurethral resection followed by a standard six-week induction of intravesical BCG. Twelve days after the final instillation, he developed isolated, severe neck extensor weakness resulting in dropped head syndrome (antecollis). Following an unrevealing cervical magnetic resonance imaging scan and the failure of empirical conservative management, a comprehensive neurophysiological evaluation was strictly performed. Concentric needle electromyography of the splenius capitis muscle revealed focal myopathic alterations, including early recruitment of small motor unit potentials, positive sharp waves, and fibrillation potentials. Crucially, low-frequency repetitive nerve stimulation (RNS) of the spinal accessory nerve, recording from the trapezius, demonstrated a significant, diagnostic decremental response of the compound muscle action potential amplitude. Serological assays confirmed highly elevated anti-acetylcholine receptor antibodies. Chest computed tomography excluded thymoma, establishing the diagnosis of very late-onset generalized MG (MGFA class IIb). Initial symptomatic monotherapy with pyridostigmine lacked efficacy. However, targeted therapy combining oral prednisone (0.5 mg/kg/day) and pyridostigmine induced a dramatic, rapid resolution of the antecollis and subsequent dysphagia. Corticosteroids were progressively tapered and definitively discontinued after six months, achieving sustained clinical remission without relapses. We report the third formally documented case of very late-onset generalized MG triggered by intravesical BCG immunotherapy, hypothetically mediated by pathogenic epitope sharing between mycobacterial and self-antigens. This case distinctly highlights the pivotal diagnostic utility of RNS in differentiating acute atypical axial weakness. Furthermore, it demonstrates that BCG-induced MG exhibits a highly favourable, fully reversible prognosis following prompt, targeted corticosteroid intervention.
- Open Access
- 5 August 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (4) , 1256-1262
Imaging of Facial Muscles in Facioscapulohumeral Muscular Dystrophy: An Exploratory Study Comparing Magnetic Resonance Imaging and Ultrasound
Aims: Facioscapulohumeral muscular dystrophy (FSHD) is a genetic progressive muscle disorder often presenting with facial weakness. However, imaging studies specifically evaluating facial muscle involvement and its relationship with clinical severity remain limited. This preliminary study explored magnetic resonance imaging (MRI) and ultrasound (US) assessment of facial muscle involvement and correlations with clinical severity. Methods: This single‐center prospective study enrolled 12 genetically confirmed FSHD1 patients (mean age 57.8 years). Clinical evaluation included the FSHD score, Comprehensive Clinical Evaluation Form (CCEF), and Facial Weakness Score (FWS). Muscle thickness of the orbicularis oris (OOr) and zygomaticus major (ZMj) was measured on both MRI and US, while MRI was additionally used for qualitative assessment of muscle bulk. Inter‐rater reliability was assessed for imaging measurements. Results: MRI and US showed comparable facial muscle thickness, with mean ZMj thickness of 2.34 ± 0.75 mm and 2.12 ± 0.55 mm, and OOr thickness of 2.28 ± 0.70 mm and 2.20 ± 0.67 mm, respectively. Inter‐rater reliability for MRI was high (ICC = 0.84), and reduced ZMj thickness showed moderate to strong correlation with greater disease severity ( ρ up to 0.87, p < 0.001) and impaired facial gestures ( ρ = 0.50–0.77, p < 0.05). Discussion: Despite the small sample size, MRI, and US assessment of facial muscles correlated with clinical severity and functional outcomes in FSHD, supporting their use as complementary tools. Longitudinal studies are required to establish imaging's role in monitoring changes over time.
- 5 August 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (4) , 1256-1262
Open AccessImaging of Facial Muscles in Facioscapulohumeral Muscular Dystrophy: An Exploratory Study Comparing Magnetic Resonance Imaging and Ultrasound
Aims: Facioscapulohumeral muscular dystrophy (FSHD) is a genetic progressive muscle disorder often presenting with facial weakness. However, imaging studies specifically evaluating facial muscle involvement and its relationship with clinical severity remain limited. This preliminary study explored magnetic resonance imaging (MRI) and ultrasound (US) assessment of facial muscle involvement and correlations with clinical severity. Methods: This single‐center prospective study enrolled 12 genetically confirmed FSHD1 patients (mean age 57.8 years). Clinical evaluation included the FSHD score, Comprehensive Clinical Evaluation Form (CCEF), and Facial Weakness Score (FWS). Muscle thickness of the orbicularis oris (OOr) and zygomaticus major (ZMj) was measured on both MRI and US, while MRI was additionally used for qualitative assessment of muscle bulk. Inter‐rater reliability was assessed for imaging measurements. Results: MRI and US showed comparable facial muscle thickness, with mean ZMj thickness of 2.34 ± 0.75 mm and 2.12 ± 0.55 mm, and OOr thickness of 2.28 ± 0.70 mm and 2.20 ± 0.67 mm, respectively. Inter‐rater reliability for MRI was high (ICC = 0.84), and reduced ZMj thickness showed moderate to strong correlation with greater disease severity ( ρ up to 0.87, p < 0.001) and impaired facial gestures ( ρ = 0.50–0.77, p < 0.05). Discussion: Despite the small sample size, MRI, and US assessment of facial muscles correlated with clinical severity and functional outcomes in FSHD, supporting their use as complementary tools. Longitudinal studies are required to establish imaging's role in monitoring changes over time.
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3)
Motor, Extrapyramidal, and Cognitive Involvement in RFC1 Disease
Biallelic intronic repeat expansions in the replication factor C subunit 1 (RFC1) gene are a common cause of cerebellar ataxia, neuropathy, vestibular areflexia syndrome and other late-onset ataxias. Recent evidence suggests a broader phenotypic spectrum. This systematic review and meta-analysis evaluated the prevalence and features of motor neuron, extrapyramidal, and cognitive involvement in RFC1 disease. We systematically searched PubMed, Scopus, and Web of Science for studies reporting motor neuron, extrapyramidal, or cognitive involvement in RFC1 disease from inception to March 2025. Eligible sources comprised research articles and case reports/series on genetically confirmed cases. Extracted data included publication details, study design, location, and individual participant data (IPD) covering demographics, signs, and symptoms. When needed, IPD were obtained from corresponding authors. Random-effects models were used to estimate pooled prevalences (95% CIs). Univariable mixed-effects logistic regression accounted for clustering within studies, with multivariable models including variables with p < 0.10 in univariate analyses. Of 729 articles, 37 were included in the systematic review and 36 (874 patients) in the proportion meta-analyses. For IPD meta-analysis, 30 cohorts provided data on 312 patients (mean age 66.91 ± 10.76 years; median disease duration 12 [interquartile range 7–18] years; 51.5% male). Upper and lower motor neuron signs were present in 18% (95% CI 6%–34%) and 11% (95% CI 2%–24%). Patients with the ACAGG pentanucleotide repeat expansion (biallelic or compound heterozygous with an AAGGG expansion) had higher odds of muscle atrophy (OR 17.90, p 0.001) and weakness (OR 11.69, p 0.001); men had an increased likelihood of muscle atrophy (OR 2.71, p = 0.038). The pooled prevalence of parkinsonism and cognitive impairment was 8% (95% CI 1%–18%) and 31% (95% CI 13%–53%), with prominent executive-attention deficits. Cognitive decline was more likely with longer disease duration (OR 1.04, p = 0.047) and in biallelic AAGGG carriers vs ACAGG (ACAGGexp: OR 0.13, p = 0.041). Motor neuron, extrapyramidal, and cognitive involvement may extend the phenotypic spectrum of RFC1 disease. Still, their true prevalence remains uncertain due to heterogeneity across studies, with potential overestimation from publication bias favoring atypical cases and underestimation when subtle signs are not systematically investigated. Larger multicenter cohorts with standardized assessments are needed to clarify their clinical relevance.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (3)
Open AccessMotor, Extrapyramidal, and Cognitive Involvement in RFC1 Disease
Biallelic intronic repeat expansions in the replication factor C subunit 1 (RFC1) gene are a common cause of cerebellar ataxia, neuropathy, vestibular areflexia syndrome and other late-onset ataxias. Recent evidence suggests a broader phenotypic spectrum. This systematic review and meta-analysis evaluated the prevalence and features of motor neuron, extrapyramidal, and cognitive involvement in RFC1 disease. We systematically searched PubMed, Scopus, and Web of Science for studies reporting motor neuron, extrapyramidal, or cognitive involvement in RFC1 disease from inception to March 2025. Eligible sources comprised research articles and case reports/series on genetically confirmed cases. Extracted data included publication details, study design, location, and individual participant data (IPD) covering demographics, signs, and symptoms. When needed, IPD were obtained from corresponding authors. Random-effects models were used to estimate pooled prevalences (95% CIs). Univariable mixed-effects logistic regression accounted for clustering within studies, with multivariable models including variables with p < 0.10 in univariate analyses. Of 729 articles, 37 were included in the systematic review and 36 (874 patients) in the proportion meta-analyses. For IPD meta-analysis, 30 cohorts provided data on 312 patients (mean age 66.91 ± 10.76 years; median disease duration 12 [interquartile range 7–18] years; 51.5% male). Upper and lower motor neuron signs were present in 18% (95% CI 6%–34%) and 11% (95% CI 2%–24%). Patients with the ACAGG pentanucleotide repeat expansion (biallelic or compound heterozygous with an AAGGG expansion) had higher odds of muscle atrophy (OR 17.90, p 0.001) and weakness (OR 11.69, p 0.001); men had an increased likelihood of muscle atrophy (OR 2.71, p = 0.038). The pooled prevalence of parkinsonism and cognitive impairment was 8% (95% CI 1%–18%) and 31% (95% CI 13%–53%), with prominent executive-attention deficits. Cognitive decline was more likely with longer disease duration (OR 1.04, p = 0.047) and in biallelic AAGGG carriers vs ACAGG (ACAGGexp: OR 0.13, p = 0.041). Motor neuron, extrapyramidal, and cognitive involvement may extend the phenotypic spectrum of RFC1 disease. Still, their true prevalence remains uncertain due to heterogeneity across studies, with potential overestimation from publication bias favoring atypical cases and underestimation when subtle signs are not systematically investigated. Larger multicenter cohorts with standardized assessments are needed to clarify their clinical relevance.
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (6)
Phenotype-Genotype Correlations in Early-Onset Myelin Protein Zero–Related Neuropathies
Myelin protein zero (MPZ)–related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (s = 0.56; p < 0.001), suggesting disease progression in this cohort. Destabilizing variants were associated with earlier onset (p < 0.001), upper limb involvement (p < 0.001), impaired ambulation (p < 0.01), scoliosis (p < 0.01), and faster progression as measured by CMTES/age (0.24 vs 0.11 CMTES/year). After excluding the c.245A>C, p.Y82S outlier (highly destabilizing but not UPR-activating), ∆∆G values showed significant correlations with age at onset (rs = 0.54, p = 0.030), CMTES (rs = −0.82, p < 0.001), and progression (rs = −0.60, p = 0.032). Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (6)
Open AccessPhenotype-Genotype Correlations in Early-Onset Myelin Protein Zero–Related Neuropathies
Myelin protein zero (MPZ)–related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (s = 0.56; p < 0.001), suggesting disease progression in this cohort. Destabilizing variants were associated with earlier onset (p < 0.001), upper limb involvement (p < 0.001), impaired ambulation (p < 0.01), scoliosis (p < 0.01), and faster progression as measured by CMTES/age (0.24 vs 0.11 CMTES/year). After excluding the c.245A>C, p.Y82S outlier (highly destabilizing but not UPR-activating), ∆∆G values showed significant correlations with age at onset (rs = 0.54, p = 0.030), CMTES (rs = −0.82, p < 0.001), and progression (rs = −0.60, p = 0.032). Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.
- Open Access
- 2 May 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (3) , 102066
Imaging for inflammatory neuropathies
- 2 May 2025
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 39 (3) , 102066
Open AccessImaging for inflammatory neuropathies
- Open Access
- 4 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3377
Basic Pathological Mechanisms in Peripheral Nerve Diseases
Pathological changes and the cellular and molecular mechanisms underlying axonopathy and myelinopathy are key to understanding a wide range of inherited and acquired peripheral nerve disorders. While the clinical indications for nerve biopsy have diminished over time, its diagnostic value remains significant in select conditions, offering a unique window into the pathophysiological processes of peripheral neuropathies. Evidence highlights the symbiotic relationship between axons and myelinating Schwann cells, wherein disruptions in axo-glial interactions contribute to neuropathogenesis. This review synthesizes recent insights into the pathological and molecular underpinnings of axonopathy and myelinopathy. Axonopathy encompasses Wallerian degeneration, axonal atrophy, and dystrophy. Although extensively studied in traumatic nerve injury, the mechanisms of axonal degeneration and Schwann cell-mediated repair are increasingly recognized as pivotal in non-traumatic disorders, including dying-back neuropathies. We briefly outline key transcription factors, signaling pathways, and epigenetic changes driving axonal regeneration. For myelinopathy, we discuss primary segmental demyelination and dysmyelination, characterized by defective myelin development. We describe paranodal demyelination in light of recent findings in nodopathies, emphasizing that it is not an exclusive indicator of demyelinating disorders. This comprehensive review provides a framework to enhance our understanding of peripheral nerve pathology and its implications for developing targeted therapies.
- 4 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3377
Open AccessBasic Pathological Mechanisms in Peripheral Nerve Diseases
Pathological changes and the cellular and molecular mechanisms underlying axonopathy and myelinopathy are key to understanding a wide range of inherited and acquired peripheral nerve disorders. While the clinical indications for nerve biopsy have diminished over time, its diagnostic value remains significant in select conditions, offering a unique window into the pathophysiological processes of peripheral neuropathies. Evidence highlights the symbiotic relationship between axons and myelinating Schwann cells, wherein disruptions in axo-glial interactions contribute to neuropathogenesis. This review synthesizes recent insights into the pathological and molecular underpinnings of axonopathy and myelinopathy. Axonopathy encompasses Wallerian degeneration, axonal atrophy, and dystrophy. Although extensively studied in traumatic nerve injury, the mechanisms of axonal degeneration and Schwann cell-mediated repair are increasingly recognized as pivotal in non-traumatic disorders, including dying-back neuropathies. We briefly outline key transcription factors, signaling pathways, and epigenetic changes driving axonal regeneration. For myelinopathy, we discuss primary segmental demyelination and dysmyelination, characterized by defective myelin development. We describe paranodal demyelination in light of recent findings in nodopathies, emphasizing that it is not an exclusive indicator of demyelinating disorders. This comprehensive review provides a framework to enhance our understanding of peripheral nerve pathology and its implications for developing targeted therapies.
- Open Access
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7194
Low-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: A Preliminary Study
Background. Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Previous research showed that creatine supplementation may be a relatively inexpensive, safe, and effective way to mitigate statin toxicity to the muscle. Methods. We thus investigated the tolerability and effectiveness of creatine supplementation in consecutive patients with statin myopathy, as observed at our Cardiology or Neurology outpatient services for previous cardiac or cerebral ischemic disease. Results. We confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elderly population. Eleven of the thirteen enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at a dose of 1 g. t.i.d., lower than usually prescribed in the international literature and within the recommendations of health agencies like the Italian Ministry of Health. Conclusion. Creatine supplementation may improve statin myopathy in its milder and/or earlier form when serum CK is not elevated. Since creatine is relatively inexpensive, its supplementation may be used instead of switching from statins to the very expensive second-line anti-cholesterol treatments.
- 27 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7194
Open AccessLow-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: A Preliminary Study
Background. Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Previous research showed that creatine supplementation may be a relatively inexpensive, safe, and effective way to mitigate statin toxicity to the muscle. Methods. We thus investigated the tolerability and effectiveness of creatine supplementation in consecutive patients with statin myopathy, as observed at our Cardiology or Neurology outpatient services for previous cardiac or cerebral ischemic disease. Results. We confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elderly population. Eleven of the thirteen enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at a dose of 1 g. t.i.d., lower than usually prescribed in the international literature and within the recommendations of health agencies like the Italian Ministry of Health. Conclusion. Creatine supplementation may improve statin myopathy in its milder and/or earlier form when serum CK is not elevated. Since creatine is relatively inexpensive, its supplementation may be used instead of switching from statins to the very expensive second-line anti-cholesterol treatments.
- Open Access
- 26 September 2024
- Published by MDPI AG in Preprints.org
Low-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: An Observational, Preliminary Study
Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Creatine supplementation may be a safe, effective and cheap alternative this shift. We investigated tolerability and possible effectiveness of creatine supplementation in statin myopathy. Our data confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elder population. In fact, 11 of the 13 enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at the dose of 1g. t.i.d., lower that usually prescribed in international literature and within the recommendations of health agencies like the Italian Ministry of Health. Thus, creatine supplementation may improve statin myopathy in its milder and/or earlier form, when serum CK is not elevated. Moreover, creatine supplementation may prevent or delay switching from statins to the very expensive second-line anti-cholesterol treatments.
- 26 September 2024
- Published by MDPI AG in Preprints.org
Open AccessLow-Dose Creatine Supplementation May Be Effective in Early-Stage Statin Myopathy: An Observational, Preliminary Study
Statins are the main cholesterol-lowering treatments, but often they are stopped because of statin myopathy. Expensive second-line treatments are then prescribed, causing a burden on the health system. Creatine supplementation may be a safe, effective and cheap alternative this shift. We investigated tolerability and possible effectiveness of creatine supplementation in statin myopathy. Our data confirmed previous findings showing that creatine supplementation is safe and well tolerated even in this elder population. In fact, 11 of the 13 enrolled patients completed the study, and only one patient interrupted the study because of a creatine-related issue (elevation of serum creatinine). Creatine supplementation significantly reduced the Shewmon and Craig’s “myopathy score”, while it did not reduce serum creatine kinase (CK), a marker of muscle structural damage. Notably, creatine supplementation was effective at the dose of 1g. t.i.d., lower that usually prescribed in international literature and within the recommendations of health agencies like the Italian Ministry of Health. Thus, creatine supplementation may improve statin myopathy in its milder and/or earlier form, when serum CK is not elevated. Moreover, creatine supplementation may prevent or delay switching from statins to the very expensive second-line anti-cholesterol treatments.